trending Market Intelligence /marketintelligence/en/news-insights/trending/tygzndkl8vqlfdm5du2kdg2 content esgSubNav
In This List

BioStem Technologies to acquire Mexican stem cell company

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


BioStem Technologies to acquire Mexican stem cell company

Florida's BioStem Technologies Inc. signed a letter of intent to fully acquire Grupo Impulso De Incentivacion Para Nuevas Tecnologias, or GIINT, through a stock swap.

Financial terms of the deal, which remains subject to due diligence, were not disclosed.

The deal will add Mexico-based GIINT's stem cell research, development, storage, and advanced treatments and protocols to BioStem's knowledge in the stem cell and regenerative medicine sectors, BioStem Technologies CEO Henry Van Vurst said in a news release.

GIINT assets also include a laboratory for processing stem cells and partnerships with over 20 health institutions in Mexico and around the world.

GIINT provides regenerative medicine services through its units Indebioc and Store-a-Cell.

BioStem is focused on pharmaceuticals and regenerative medicine.